GENERAL COMMENTARY article
Sec. Thyroid Endocrinology
Volume 8 - 2017 | https://doi.org/10.3389/fendo.2017.00028
TSH Receptor Antibody Functionality and Nomenclature
- Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
A commentary on
by Smith TJ, Hegedus LN. Engl J Med (2016) 375(16):1552–65. doi:10.1056/NEJMra1510030
This general commentary on the above, recently published New England Journal of Medicine review article wishes to clarify both the nomenclature as well as the role of autoantibodies (Ab) to the TSH receptor (TSH-R) pertaining to the serological diagnosis of Graves’ disease (GD).
Various terms have been used to describe the different types of TSH-R-Ab. It is important for the clinician to be aware of the different nomenclature as this will frequently reflect which assay is performed by the laboratory (Table 1). TSH-R-Ab, often referred to as TRAb, refers to any type of Ab interacting specifically with the TSH-R. Because these Ab are commonly assessed in a competitive binding assay, they are referred to as TSH-R-binding inhibitory immunoglobulins (TBII). By contrast, cell-based bioassays measure either TSH-R stimulatory antibodies (TSAb) or TSH-R-stimulating immunoglobulins, or alternately TSH-R-blocking antibodies (TBAb) or TSH-R-blocking immunoglobulins. Alternative terminologies for blocking antibodies are TSH-R-stimulating blocking Ab or TSH-R-blocking Ab (TRBAb). In this commentary, we will use TSH-R-Ab as a general term to refer to anti-TSH-R-Ab irrespective of the specific assay used. We will use TBII to refer to the Ab measured via binding assays, whereas Ab measured via bioassays will be referred to as TSAb for stimulatory and TBAb for blocking Ab.
Graves’ disease is caused by persistent, unregulated stimulation of thyroid cells by TSH-R-stimulating Ab (TSAb) that activate the TSH-R (1). TSAb, like TSH, bind primarily to the large amino terminal ectodomain of the TSH-R and activate the cAMP signal transduction pathway leading to stimulation of thyroid hormone production and proliferation of thyrocytes. Since the discovery of TSAb as the causative agent of GD, there have been numerous studies that have demonstrated the significance of the levels of these Ab during the course of the disease as well as during antithyroid drug treatment in both adults and children (2, 3). Other types of TSH-R antibodies can antagonize or block the action of TSH and in doing so cause hypothyroidism in certain patients with various types of autoimmune thyroiditis, particularly Hashimoto’s thyroiditis. TSH-R antibodies that neither induce the cAMP signal pathway nor block the binding of TSH are referred to as neutral or recently “cleavage” Ab and currently are not known to have a functional effect (4). There is evidence, however, that neutral Ab may induce signaling pathways distinct from the cAMP pathway and may induce apoptosis (5).
As strongly recommended in the recently published hyperthyroidism guidelines of the American Thyroid Association (6), measurement of TSH-R-Ab is indicated both for the accurate and early diagnosis of autoimmune induced hyperthyroidism as well as during the management of patients with GD. Functional TSH-R-stimulating antibodies (TSAb) are causative of both the hyperthyroidism and the extra thyroidal manifestations of GD (7). TSAb can be sensitively and exclusively measured with validated bioassays that are available worldwide (8–11). In particular, the analytical performance and clinical utility of a FDA-cleared, stimulatory TSH-R bioassay in a large collective of patients with GD, both prior to as well as during medical antithyroid treatment, has been shown (12). In addition, a multicenter trial involving seven American and European academic referral centers confirmed the very high specificity, sensitivity, and positive and negative predictive values of this tool for the diagnosis of GD in children (13). Standardization and calibration of this bioassay, using a purely stimulatory human monoclonal TSH-R-Ab as international standard, allowed results to be reported in international units per liter (14). This has facilitated comparison of bioassay results with commercially available automated TSH-R-binding or TBII assays. A recent comparative study of seven immunoassays has shown that bioassays for TSH-R-Ab are more sensitive than the automated binding assays and exclusively differentiate between stimulatory and blocking Ab activity (15). Also, TSAb are a highly sensitive and predictive biomarker of the extra thyroidal manifestations of GD (16–18). Furthermore, the clinical relevance of the measurement of TSH-R-Ab and of TSAb in particular, during pregnancy in patients with autoimmune thyroid disease, was recently documented in a newborn with fetal/neonatal autoimmune thyrotoxicosis (19). Finally, incorporation and early utilization of TSAb into current diagnostic algorithms was shown to confer a 46% shortened time to diagnosis of GD and a cost savings of 47% (20).
The two authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest Statement
TD has nothing to disclose. GK consults for Quidel, USA.
1. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med (2016) 375(16):1552–65. doi:10.1056/NEJMra1510030
2. Botero D, Brown RS. Bioassay of thyrotropin receptor antibodies with Chinese hamster ovary cells transfected with recombinant human thyrotropin receptor: clinical utility in children and adolescents with Graves disease. J Pediatr (1998) 132(4):612–8.
3. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid (2007) 17(11):1103–7. doi:10.1089/thy.2007.0072
4. Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves’ disease and regulate selective signaling cascades. Endocrinology (2010) 151(11):5537–49. doi:10.1210/en.2010-0424
5. Morshed SA, Ma R, Latif R, Davies TF. How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis. J Autoimmun (2013) 47:17–24. doi:10.1016/j.jaut.2013.07.009
6. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid (2016) 26(10):1343–421. doi:10.1089/thy.2016.0229
7. Bahn RS. Graves’ ophthalmopathy. N Engl J Med (2010) 362(8):726–38. doi:10.1056/NEJMra0905750
8. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev (2010) 10(2):116–22. doi:10.1016/j.autrev.2010.08.018
9. Kahaly GJ. Bioassays for TSH receptor antibodies: quo vadis? Eur Thyroid J (2015) 4(1):3–5. doi:10.1159/000375445
10. FIRS Laboratories, RSR Ltd. Assay Service. Thyroid Stimulating Autoantibody Bioassay. Available from: http://www.rsrltd.com/assay_service.html (accessed September 20, 2013).
11. Araki N, Iida M, Amino N, Morita S, Ide A, Nishihara E, et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin. Eur Thyroid J (2015) 4(1):14–9. doi:10.1159/000371740
12. Leschik JJ, Diana T, Olivo PD, Konig J, Krahn U, Li Y, et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol (2013) 139(2):192–200. doi:10.1309/AJCPZUT7CNUEU7OP
13. Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, Konig J, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves’ disease – a multicenter study. J Clin Endocrinol Metab (2014) 99(5):1648–55. doi:10.1210/jc.2013-4026
14. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ. Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid (2015) 25(2):169–75. doi:10.1089/thy.2014.0346
15. Diana T, Wuster C, Kanitz M, Kahaly GJ. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest (2016) 39(10):1159–65. doi:10.1007/s40618-016-0478-9
16. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab (2010) 95(5):2123–31. doi:10.1210/jc.2009-2470
17. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology (2011) 118(11):2279–85. doi:10.1016/j.ophtha.2011.03.030
18. Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J. Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab (2016) 101(5):1998–2004. doi:10.1210/jc.2016-1220
19. Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, et al. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto’s thyroiditis. J Clin Endocrinol Metab (2017) 102(1):6–9. doi:10.1210/jc.2016-2999
20. McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care (2012) 18(1):e1–14.
Keywords: Graves’ disease, functional TSH receptor antibodies, stimulating antibodies, blocking antibodies, nomenclature
Citation: Kahaly GJ and Diana T (2017) TSH Receptor Antibody Functionality and Nomenclature. Front. Endocrinol. 8:28. doi: 10.3389/fendo.2017.00028
Received: 10 January 2017; Accepted: 01 February 2017;
Published: 15 February 2017
Edited by:Cesidio Giuliani, University of Chieti-Pescara, Italy
Reviewed by:Alessandro Antonelli, University of Pisa, Italy
Copyright: © 2017 Kahaly and Diana. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: George J. Kahaly, firstname.lastname@example.org